Results 51 to 60 of about 2,435 (141)

Investigating the Association Between Cystic Fibrosis and Colorectal Neoplasia: A Matched Case–Control Study

JGH Open, Volume 10, Issue 7, July 2026.
ABSTRACT Background Cystic fibrosis (CF) is an autosomal recessive disorder that has been associated with increased risk of colorectal neoplasia and cancer (CRC). Current consensus statements recommend early screening and surveillance colonoscopies for CRC in CF, though high‐quality data supporting this remains lacking.
Dazhong Huang, Douglas Tjandra, Ammar Majeed, Gregory Snell, Stuart K. Roberts, Gregor Brown, Alex Boussioutas, Peter Wark, Shara Ket   +8 more
wiley   +1 more source

Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions

Pregnancy, Volume 2, Issue 4, July 2026.
Abstract Background The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth.
Hiba J. Mustafa, Yair J. Blumenfeld, Ramen H. Chmait, Jennifer L. Taylor‐Cousar, Jordana E. Hoppe, Stacey L. Martiniano, Angela Metcalf, Scott D. Sagel, Edith T. Zemanick, Alireza A. Shamshirsaz, Sylvia E. Szentpetery, Aaron T. Trimble, Elizabeth B. Burgener, Carmen Luna‐Paredes, Isabelle Sermet‐Gaudelus, Michael V. Zaretsky   +15 more
wiley   +1 more source

Delayed Diagnosis of Cystic Fibrosis and Nontuberculous Mycobacterial Infection in Refractory CRSwNP

Respirology Case Reports, Volume 14, Issue 7, July 2026.
This case describes a 31‐year‐old woman with treatment‐resistant sinus disease in which a delayed diagnosis of CF led to lung complications. It emphasises the importance of considering underlying causes like CF in unexplained, treatment‐resistant cases of chronic rhinosinusitis.
Robert Greig, Philipp Suter, Rory Chan, David Connell, Brian Lipworth   +4 more
wiley   +1 more source

Editorial: Real-world experience with CFTR modulator therapy

Frontiers in Pharmacology, 2023
Burkhard Tümmler, Burkhard Tümmler, Pierre-Régis Burgel, Pierre-Régis Burgel   +3 more
doaj   +1 more source

Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice

Acta Psychologica
Recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF).
Qian Ge, Amy Fagan, Hui Lu, Jianyang Du, Leah R. Reznikov   +4 more
doaj   +1 more source

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis

JAAD Case Reports, 2021
Rebecca H. Goldberg, BS, Natalie H. Matthews, MD, MPhil, Alexandra C. Hristov, MD, Frank Wang, MD   +3 more
doaj   +1 more source

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

Molecules
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells.
Filipa C. Ferreira, Camilla D. Buarque, Miquéias Lopes-Pacheco   +2 more
doaj   +1 more source

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Frontiers in Pharmacology, 2023
Jochen G. Mainz, Jochen G. Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier, Christina Smaczny, Anton Barucha, Lilith Bechinger, Franziska Duckstein, Ludwik Kurzidim, Ludwik Kurzidim, Patience Eschenhagen, Laura Caley, Daniel Peckham, Daniel Peckham, Carsten Schwarz   +18 more
doaj   +1 more source

Mejoría de la inflamación intestinal tras tratamiento con moduladores de la proteína CFTR en pacientes con fibrosis quística

Anales de Pediatría
Resumen: Introducción: Los tratamientos con moduladores de la proteína CFTR han mejorado la salud respiratoria y digestiva de los pacientes con fibrosis quística.
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez   +14 more
doaj   +1 more source

Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients

Anales de Pediatría (English Edition)
Introduction: Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis. Objective: To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with ...
Ruth García Romero, Concepción López Cárdenes, Elena Crehuá Gaudiza, Marina Álvarez Beltrán, Mercedes Murray Hurtado, Carlos Tutau Gómez, Inés Loverdos Eseverri, Encarni Torcuato Rubio, Camila García Volpe, Enrique Salcedo Lobato, María Medina Martínez, Carmen Martin Fernández, Ana Moreno Álvarez, Ana Reyes Domínguez, David González Jiménez, Saioa Vicente Santamaría, Ana Tabares González, Jose Ramon Gutierrez Martinez, Sara Sierra San Nicolás, Pilar Ortiz Pérez, Luis Peña Quintana   +20 more
doaj   +1 more source